This article provides the information you need to make that evaluation - based on what is publicly verifiable today
Zitzmann, M
696 Other efforts have attempted to broaden the reach and accessibility of interventions for dementia caregivers through the use of technologies (for instance, videophone delivery and online training), 697 , 698 , 699 , 700 , 701 , 702 , 703 , 704 , 705 while others have disseminated evidencebased dementia care interventions into communitybased programs and health care systems
Liposomal glutathione represents a more advanced approach
Add-on to 1-3 oral anti-hyperglycemic agents (metformin, sulfonylurea, or SGLT-2 inhibitor) SURPASS-4 (NCT03730662) was a 104-week open-label trial (52-week primary endpoint) that randomized 2002 adult patients with type 2 diabetes mellitus with increased cardiovascular risk to subcutaneous MOUNJARO 5 mg, MOUNJARO 10 mg, MOUNJARO 15 mg once weekly, or insulin glargine 100 units/mL once daily (1:1:1:3 ratio) on a background of metformin (95%) and/or sulfonylureas (54%) and/or SGLT2 inhibitors (25%)
Dose changes need medical guidance because too little support may lead to appetite rebound, while too much can increase side effects or make nutrition harder
